Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, Immunogenicity and Pharmacokinetic Profile of Single Dose of JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) Injection in Healthy Volunteers

Next Previous
Trial Profile

Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, Immunogenicity and Pharmacokinetic Profile of Single Dose of JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) Injection in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JS 005 (Primary)
  • Indications Autoimmune disorders; Inflammation; Psoriatic arthritis
  • Focus Adverse reactions
  • Sponsors Shanghai Junshi Biosciences

Most Recent Events

  • 30 Aug 2020 Status changed from not yet recruiting to recruiting, according to a Junshi Biosciences media release.
  • 30 Aug 2020 According to a Junshi Biosciences media release, the first subject was dosed in this study in May 2020. At present, the study has completed random enrollment.
  • 30 Mar 2020 According to a Junshi Biosciences media release, the company has received the Clinical Trial Approval from NMPA in August 2019. Phase I clinical trial of JS005 is expected to complete the first patient enrollment in the first half of 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top